While drug developers, healthcare practitioners and patients all rejoice at the advent of a golden age of scientific advancement in medicine – symbolized by recent radical breakthroughs in all manners…
With the USD 62 billion deal from Japan’s Takeda Pharmaceutical to buy Irish firm Shire finally agreed after months of wrangling, we asked PharmaBoardroom’s readers whether this deal would herald…
A new regulation is helping Portugal’s market access conditions for pharmaceuticals catch up with those of other developed European markets, with a jump in the number of approvals for 2017.…
The global pharmaceutical outsourcing market was estimated to be USD 115.7 billion in 2016, of which 49 percent is accounted for by contract research organisations (CROs). Within India, the contract…
Despite its relative youth, Canada’s medical cannabis industry is already presenting some of the characteristics of the much more mature pharmaceutical industry. There is consolidation as well as the first…
According to the World Bank, Ecuador had a GDP per capita of USD 5,970 in 2014; a comparable level to USD 6,000 in Peru and 5,800 in Colombia for the…
As the Lithuanian market matures, profound shifts have been taking place in the arena of human resources and how drug developers go about identifying, acquiring and retaining the personnel they…
Several smaller pharmaceutical companies – Taiho, Valneva, Mallinckrodt, Théa and Intercept Pharma – have chosen to set up operations in Canada very recently, recognizing the potential for product launches and development…
With over 120,000 people whose lives are affected by the disease in Lithuania; diabetes stands as one of the country’s major health issues today. Furthermore, as Marijus Valatka, general manager…
Despite the global R&D excitement around oncology, cardiovascular death still remains the world’s largest killer, and according to OECD data, accounts for roughly a third of all mortalities. This trend…
Lithuania’s biotech sector has grown by between 20 and 25 percent over the last five years and accounts for over one percent of the entire country’s GDP. Key industry stakeholders…
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in…
See our Cookie Privacy Policy Here
